🔎 Trials Near Me

Home › Attention Deficit Hyperactivity Disorder › NCT07594652

Medication Treatment of ADHD in Pediatric Epilepsy

RecruitingPhase 4

Use of JornayPM® to Treat ADHD in Pediatric Epilepsy

Who can join

Ages 6 to 17 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Inclusion criteria:

  * Established diagnosis of epilepsy that requires treatment with anti-seizure medication.
  * No episodes of seizure clusters or status epilepticus within 30 days prior to entry into the study.
  * Diagnosis of ADHD with functional impairment.
  * Good general health as determined by medical history and physical examination, including stable vital signs.
  * Participant or legal caregiver capable of providing informed consent and fully capable of monitoring the subject's disease process and compliance with treatment.

Exclusion Criteria:

* • Previous allergic or hypersensitivity reactions to stimulant medicines including Jornay PM®

  * Active substance abuse or dependence within 30 days of enrollment
  * Epilepsy that is unstable or with seizure frequency that exceeds four events per month, based on an average over the previous three months
  * DSM-V diagnosis of psychotic illness or imminent risk of harm to self or others.
  * Current use of stimulants to treat ADHD
  * Serious or unstable medical or neurologic conditions such as HIV, liver or kidney disease, cancer or diabetes.
  * Unstable cardiac illness such as arrythmias or cardiomyopathy.
  * Participation in a previous experimental drug study within 30 days of baseline visit.
  * Estimated IQ\<70 as indicated by clinical assessment to the degree that rating scales may be invalid
  * Insufficient capacity of caregiver or legal guardian to understand and appropriately consent for study procedures

About the study

This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy.

What is being tested

Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Participants: 25 · Started: May 29, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07594652

Locations in the U.S.

MarylandKennedy Krieger Institute, Baltimore

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.